What does AVTX-009 — issuance of common stock in cash mean?

This represents the gross proceeds received from the issuance of new common equity shares for cash, typically through public offerings or private placements. It serves as a primary mechanism for raising capital to fund ongoing research, development, and operational expenses in a clinical-stage biotechnology environment. Monitoring this metric helps investors assess the company's ability to access capital markets and the potential for shareholder dilution.

Avalo Therapeutics AVTX AVTX-009 — Issuance of common stock in cash

Similar metrics at other companies

AXSMStock Issuance Proceeds

$6.34M-67.7%

RVMDStock Issuance Proceeds

$12.21M+1,270%

CYTKStock Issuance Proceeds

$11.35M—

INSMStock Issuance Proceeds

$30.31M+2.1%

UMH

UMHStock Issuance Proceeds

$1.31M-26.5%

RVMDProceeds From Issuance Of Common Stock From At The Market Offering

$226.73M—

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$954.59M+1,783%

Enterprise value$929.6M-1,342%

P/S1,909.2×+1,868×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueNewIssues.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's avtx-009 — issuance of common stock in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's AVTX-009 — issuance of common stock in cash?: Avalo Therapeutics (AVTX) reported AVTX-009 — issuance of common stock in cash of $5.13M in Q2 2026.
What does AVTX-009 — issuance of common stock in cash mean?: This represents the gross proceeds received from the issuance of new common equity shares for cash, typically through public offerings or private placements. It serves as a primary mechanism for raising capital to fund ongoing research, development, and operational expenses in a clinical-stage biotechnology environment. Monitoring this metric helps investors assess the company's ability to access capital markets and the potential for shareholder dilution.